OCGN SH討論區(6)之 妹到2046
山中無山莫山山
1001 回覆
10 Like
1 Dislike
第 1 頁第 2 頁第 3 頁第 4 頁第 5 頁第 6 頁第 7 頁第 8 頁第 9 頁第 10 頁第 11 頁第 12 頁第 13 頁第 14 頁第 15 頁第 16 頁第 17 頁第 18 頁第 19 頁第 20 頁第 21 頁第 22 頁第 23 頁第 24 頁第 25 頁第 26 頁第 27 頁第 28 頁第 29 頁第 30 頁第 31 頁第 32 頁第 33 頁第 34 頁第 35 頁第 36 頁第 37 頁第 38 頁第 39 頁第 40 頁第 41 頁
巴打諗住今次幾錢放
我就係記得你六個幾入咗4000股，九蚊放咗
又黎
今次一次過gme amc 大麻股
今次一次過gme amc 大麻股
但係果陣2.幾落
我預備好了
祝大家旗開得勝
仆街
真係過哂去gme賭場
預左
每drop 5毫加一轉 夠疆drop到2蚊 屌佢個閪
等下星期啦 呢個星期大戶要割賭徒
先轉舊經濟 宜家重開賭埸
先轉舊經濟 宜家重開賭埸
https://www.nasdaq.com/articles/ocugen-could-still-be-undervalued-if-its-covid-19-vaccine-gets-ok-2021-02-22
'Recently, an H.C. Wainwright analyst said that Covaxin “has generated antibody levels comparable to those in human convalescent serum.” This apparently bodes well for the vaccine getting approved. Cantor Fitzgerald analyst Kristen Kluska said that it is a whole-virion vaccine. This means it targets the whole virus unlike other established vaccines against the specific proteins of the coronavirus.'
'Recently, an H.C. Wainwright analyst said that Covaxin “has generated antibody levels comparable to those in human convalescent serum.” This apparently bodes well for the vaccine getting approved. Cantor Fitzgerald analyst Kristen Kluska said that it is a whole-virion vaccine. This means it targets the whole virus unlike other established vaccines against the specific proteins of the coronavirus.'
'...Let’s assume that Ocugen will charge $25 per dose for Covaxin.
Next, let’s assume that just 10% of the U.S. population gets the Covaxin vaccine, or 33 million people. Therefore, the total revenue to the Bharat Biotech-Ocugen partnership will be $825 million. Let’s say 20% of that goes to overhead and market costs. The profits to be distributed will be $660 million.
Now Ocugen gets to have 45% of that $660 million in profits, or $297 million. Let’s call it $300 million. Here is how I would value that. Assuming the vaccine is good for 10 years, the revenue would work out to $3 billion. That is 58% higher than the $1.9 billion valuation for OCGN stock today.
This represents a potential price gain of up to $16.23 per share (i.e., 58% higher than the Feb. 19 price of $10.27 for OCGN stock).'
Next, let’s assume that just 10% of the U.S. population gets the Covaxin vaccine, or 33 million people. Therefore, the total revenue to the Bharat Biotech-Ocugen partnership will be $825 million. Let’s say 20% of that goes to overhead and market costs. The profits to be distributed will be $660 million.
Now Ocugen gets to have 45% of that $660 million in profits, or $297 million. Let’s call it $300 million. Here is how I would value that. Assuming the vaccine is good for 10 years, the revenue would work out to $3 billion. That is 58% higher than the $1.9 billion valuation for OCGN stock today.
This represents a potential price gain of up to $16.23 per share (i.e., 58% higher than the Feb. 19 price of $10.27 for OCGN stock).'
每日都有好消息
升完兩日又跌返咁低？
收市捱唔捱到$8呢